[AML(M7) associated with t(16;21)(p11;q22) showing relapse after unrelated bone marrow transplantation and disappearance of TLS/FUS-ERG mRNA].
A 3-year-old boy with poorly prognostic acute megakaryoblastic leukemia (AML M7) showing t(16;21)(p11;q22) karyotype underwent unrelated bone marrow transplantation (U-BMT) during his first hematological remission. The conditioning regimen consisted of BU, VP-16 and L-PAM. Engraftment was smooth, but the patient developed grade I acute GVHD. During hematological remission before U-BMT, the TLS/FUS-ERG chimeric transcript of t(16;21)(p11;q22) was consistently detectable as minimal residual disease (MRD) by RT-PCR. However, after U-BMT it soon became undetectable. There was no detectable MRD until 7 months after U-BMT, but bone marrow relapse occurred 10 months after U-BMT. We consider that U-BMT is a promising treatment for t(16;21)(p11;q22) AML. However, an intensified conditioning regimen or modification of GVHD prophylaxis is needed.
Fukushima
Y
Y
Department of Pediatrics, Matsushita Memorial Hospital.
Fujii
N
N
Tabata
Y
Y
Nishimura
Y
Y
Fusaoka
T
T
Yoshihara
T
T
Tsunamoto
K
K
Kasubuchi
Y
Y
Morimoto
A
A
Hibi
S
S
Taketani
K
K
Hayashi
Y
Y
Imashuku
S
S
D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000235:genetics / Q000628:therapy*; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis; D034702:RNA-Binding Protein FUS; D012008:Recurrence; D014178:Translocation, Genetic
D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D034702:RNA-Binding Protein FUS; C107302:TLS-ERG fusion protein, human